The effect of trimethoprim (TMP) or TMP-sulfamethoxazole (SMX) treatment on the emergence of fecal bacteria has been studied by many investigators in different countries (2, 4, 8, 10, 14, 15, (17) (18) (19) . With one exception, little or no emergence of fecal TMP-resistant strains has been found in these studies. Different findings were presented by Murray et al., who compared TMP with TMP-SMX and placebo in the prophylaxis of diarrhea among students travelling to Mexico (14) . After prophylaxis with TMP or TMP-SMX, the number of TMP-resistant Escherichia coli organisms increased markedly in both groups; in the placebo group, no increase was seen. The purpose of the present study was to evaluate the effect on fecal flora in outpatients in Finland of a 10-day treatment of urinary tract infection (UTI) with TMP or TMP-SMX.
Ninety-seven patients were studied between June and December 1982 at the Posio and Ranua Health Centers in Finland. All patients aged 16 to 64 years with acute, uncomplicated UTI were included. No antimicrobial treatment within the preceding month or treatment with TMP or SMX within the previous 3 months was allowed. Patients with known structural abnormalities of the urinary tract were excluded. Patients were alternately assigned to the TMP or TMP-SMX group. Only patients allergic to SMX changed the assignment order. TMP was used at a dose of 160 mg twice a day, and TMP-SMX was used at a dose of 160 mg + 800 mg, respectively, twice a day (Trimopan and Trimosulfa; Laakefarmos Ltd., Turku, Finland). Both treatments were continued for 10 days. Treatment of two patients was interrupted because of skin reactions (one in the TMP group and one in the TMP-SMX group).
Routine quantitative urine cultures were carried out (Uricult-dipslide procedure; Orion Diagnostica, Espoo, Finland). Stool samples were obtained before therapy, at the end of therapy (+ 1 day), and 1 month (25 to 32 days) after the end of therapy. Stool (0.5 g) was weighed, serially diluted in physiological saline, and then plated on CLED agar (Oxoid, Basingstone, Hampshire, England), MacConkey agar (Difco Laboratories, Detroit, Mich.), and lactose agar (base agar with 15 g of lactose per 1,000 ml and 1.6% bromcresol purple). All colonies differing in appearance were studied further. Bacterial strains were identified by normal routine methods including Analytical Profile Index * Corresponding author.
procedures (Analytab Products, Plainview, N.Y.; 11). A total of 956 different isolates were tested further (an average of 3.4 different strains in the first sample, 4.1 in the second sample, and 4.2 in the third sample). Susceptibility tests were carried out by the agar plate dilution method using PDM-ASM agar (AB Biodisk, Solna, Sweden) with doubling concentrations of TMP-lactate (0.125 to 1,024 ,ug/ml; Burroughs Wellcome Co., Research Triangle Park, N.C.) and SMX (2 to 1,024 jig/ml; Laakefarmos [3] ). Standard inocula of 5 x 104 to 5 x 105 CFU/ml were controlled by the most-probable-number method (9) . After multipoint inoculation, plates were incubated at 35°C for 18 h (6). Resistance breakpoints used were 8 ,ug/ml for TMP and 512 ,g/ml for SMX (6) . E. coli ATCC 25922 and Staphylococcus aureus ATCC 25923 were used as control strains. The occurrence of homological DNA sequences to TMP resistance transposon Tn7 was studied by DNA-DNA colony hybridization with a BamHI fragment of ColE1::Tn7 as a DNA probe (16 (Table 1) . Only immediately after the treatment was a significant difference in the occurrence of SMX-resistant strains observed; SMX-resistant strains occurred in 48.8 and 77.3% of patients in the TMP and TMP-SMX groups, respectively (P < 0.01; Table 2 ), and the increase was due mainly to the increase of enterococci. All TMP-resistant enterobacteria (n = 26) with MICs of 8 ,ug or more of TMP per ml were studied further by DNA hybridization. Only three strains showed homology with the Tn7 probe. These three isolates were highly resistant to TMP (MIC, >1,024 ,ug/ml) and originated in the TMP-SMX group. Two of these strains were also SMX resistant. Only 3 of the DNA hybridization-negative strains had MICs of > (12) .
However, the amount of TMP and TMP-SMX sold with no controls or for animals in Mexico is unknown.
Our results reveal an increase of TMP-resistant enterobacteria in Finland since 1976, when only one TMPresistant coliform was found in the TMP group after 4 weeks of treatment (18) . However, in both treatment groups in this study, SMX resistance seems to be at the same level as in 1976.
To evaluate the usefulness of TMP in the treatment of UTIs, a continuous follow-up is needed. We do not recommend the use of TMP in hospitals or areas where the prevalence of TMP resistance is high (5-7) . However, at present, TMP and TMP-SMX seem to be useful antimicrobial agents in the treatment of UTIs in Finland, as clinically significant emergence of TMP resistance during therapy of outpatients thus far has not been documented.
